<DOC>
	<DOCNO>NCT00531973</DOCNO>
	<brief_summary>The randomize LITE study compare liposomal doxorubin versus standard epirubicin treatment female breast cancer . In order detect early possible post-chemotherapy cardiotoxicity , tissue Doppler imaging parameter elicit transthoracic echocardiography use constitute primary co-primary end-points .</brief_summary>
	<brief_title>A Study Liposomal Doxorubicin Women With Breast Cancer Exploiting Tissue Doppler Imaging</brief_title>
	<detailed_description>The randomize LITE study compare liposomal doxorubin versus standard epirubicin within comprehensive adjuvant neo-adjuvant chemotherapy regimen woman undergo treatment breast cancer . The study enrol total 80 patient , randomize 1:1 liposomal doxorubin v epirubicin . Standard tissue Doppler imaging parameter appraise transthoracic echocardiography use constitute primary co-primary end-points . In addition , efficacy safety end-points appraise , include disease free progression .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>woman age ≥18 ≤65 year histological and/or cytological diagnosis clinically nonmetastatic breast cancer ( c/pTall , c/pNall , cM0 ) indication integrate treatment surgical intervention associate adjuvant neoadjuvant chemotherapy , endocrinological radiation therapy , include adjuvant neoadjuvant chemotherapy anthracycline ECOG ( Eastern Cooperative Oncology Group ) performance status ≤2 normal kidney , hepatic hematological function normal LV ejection fraction baseline ( ≥50 % ) negative pregnancy test fecund woman metastatic breast cancer past radiation therapy chemotherapy hypertension cardiovascular risk factor prior valvular heart disease cardiomyopathy chronic acute congestive heart failure LV systolic dysfunction ( ejection fraction &lt; 50 % ) abnormal complete blood count pregnancy breastfeed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>echocardiography</keyword>
	<keyword>neoplasia</keyword>
</DOC>